Selcia unveils new PPIases screening service
The scope of the service includes drug screening, functional assays, compound profiling as well as determining specificity of inhibition against a representative panel of enzymes. Selcia has already
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).